[177Lu]Lu-PSMA-617 has recently gained approval by the FDA (Pluvicto®), but also [177Lu]Lu-PSMA I&T has proven high efficacy and safety in treating patients with advanced prostate cancer worldwide (Bu et al. 2022; John et al. 2022; Heck et al. 2019; Hartrampf et al. 2022), with very comparable outcomes (Schuchardt et al. 2022; Hartrampf et al. 2022). The gene discussed is FOLH1; the disease is prostate carcinoma.